Date | Price Target | Rating | Analyst |
---|---|---|---|
6/25/2024 | Buy → Neutral | BTIG Research | |
7/28/2023 | $10.00 | Overweight | Piper Sandler |
6/15/2023 | $15.00 | Buy | BTIG Research |
11/12/2021 | $12.00 → $16.00 | Buy | Truist Securities |
– Ongoing Phase 1a first-in-human clinical trial continues to demonstrate proof of concept for the UNO solid tumor platform with observed early tumor responses and clinical resolution of radiation dermatitis – Phase 1a data continue to support feasibility of administering UNO at ultra-high concentrations with immune biomarkers at 50,000 parts per million (ppm) demonstrating an immunogenic response – Phase 1b protocol of UNO in combination with anti-PD-1 antibody therapy filed for regulatory approval – Phase 1a clinical data and Phase 1b study design unveiled at 2024 American Society of Oncology Annual Meeting HAMILTON, Bermuda, June 03, 2024 (GLOBE NEWSWIRE) -- Beyond C
HAMILTON, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced being selected to present on the clinical development program of its Ultra-High Concentration Nitric Oxide (UNO) at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 – June 4, 2024 at the McCormick Place Convention Center in Chicago, Illinois. In addition, the Company will host a KOL event that will highlight the ongoing clinical development of UNO (additional details below). Company Sponsored Event: Beyond Cancer will host a
No dose limiting toxicities were reported in the first cohort of ultra-high concentration of nitric oxide administered at 25,000 parts per million (PPM) Phase 1 study continues to recruit eligible patients in the next protocol defined cohort of 50,000 ppm in multiple centers in Israel HAMILTON, Bermuda, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ:XAIR) and a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced that the Phase 1 Study evaluating UNO in advanced, relapsed or refractory unresectable, primary or metastatic cutaneous and subcutan
EFFECT - Beyond Air, Inc. (0001641631) (Filer)
144 - Beyond Air, Inc. (0001641631) (Subject)
S-3 - Beyond Air, Inc. (0001641631) (Filer)
4 - Beyond Air, Inc. (0001641631) (Issuer)
4 - Beyond Air, Inc. (0001641631) (Issuer)
4 - Beyond Air, Inc. (0001641631) (Issuer)
LungFit® PH received FDA approval for the treatment of term and near-term neonates with hypoxic respiratory failure on June 28, 2022 and the first phase of U.S. commercial launch has begun Presented positive data for high-concentration nitric oxide (NO) with LungFit® PRO in hospitalized patients with community-acquired viral pneumonia, including COVID-19, at ECCMID 2022 Presented positive long-term safety data for high-concentration NO at PAS 2022 in infants hospitalized with bronchiolitis Presented positive updated interim data from the ongoing at-home LungFit® GO pilot study for nontuberculous mycobacterial lung disease at ATS 2022 Patient screening has begun for the Phase I trial of
GARDEN CITY, New York, June 14, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that it has rescheduled the reporting of the financial results for its fiscal fourth quarter and year ended March 31, 2022 to Tuesday, June 28, 2022. The Company's management team will also host its quarterly conference call and webcast at 4
GARDEN CITY, N.Y., May 16, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that it will report financial results for its fiscal fourth quarter and year ended March 31, 2022 on Thursday, June 16, 2022. The Company's management team is scheduled to host a conference call and webcast at 4:30 pm Eastern Time the same day. C
For Immediate Release: July 01, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced a request for nominations for consumer representatives to serve on advisory committees and panels for which vacancies currently exist or are expected to occur in the near future. The FDA relies on our many advisory committees to help us
BTIG Research downgraded Beyond Air from Buy to Neutral
Piper Sandler initiated coverage of Beyond Air with a rating of Overweight and set a new price target of $10.00
BTIG Research initiated coverage of Beyond Air with a rating of Buy and set a new price target of $15.00
Piper Sandler analyst Jason Bednar maintains Beyond Air (NASDAQ:XAIR) with a Overweight and lowers the price target from $7 to $3.5.
BTIG analyst Marie Thibault downgrades Beyond Air (NASDAQ:XAIR) from Buy to Neutral.
Dr. Monson is a board-certified radiation oncologist and brings over 25 years of clinical oncology experience to Beyond Cancer. Dr. Monson is a founding partner and President of California Cancer Associates for Research & Excellence (cCARE), the largest private oncology practice in California. HAMILTON, Bermuda, June 01, 2022 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ:XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced the appointment of Jedidiah Monson, M.D. to the position of Chief Medical Officer, effective June 1, 2022. "We are excited to appoint Dr. Monson as
HAMILTON, Bermuda, May 17, 2022 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ:XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced the appointment of Susan Howell Jones, CPA as Chief Financial Officer. Ms. Jones joins Beyond Cancer™ with over 30 years of international and operational financial leadership experience, including 20 years within the bioscience sector of BASF, a globally recognized chemical company. In her role as Senior Manager of Operational Accounting she was a key member of the implementation team responsible for the $4B acquisition of American Cyanamid. Follow
Dr. Colin brings four decades of clinical experience in pediatric pulmonology to Beyond Air, with research spanning respiratory physiology, Cystic Fibrosis, and lung infections culminating in over 120 peer-reviewed publications and 250 global lectures As a board-certified pediatric pulmonologist, Dr. Colin has been an active member of Beyond Air's Scientific Advisory Board since 2013 Dr. Colin has participated in over 20 clinical trials, including studies sponsored by the National Institutes of Health, Genentech, GlaxoSmithKline, and the Cystic Fibrosis Foundation's Therapeutic Development Network GARDEN CITY, N.Y., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a c
SC 13G - Beyond Air, Inc. (0001641631) (Subject)
SC 13G/A - Beyond Air, Inc. (0001641631) (Subject)
SC 13G - Beyond Air, Inc. (0001641631) (Subject)
4 - Beyond Air, Inc. (0001641631) (Issuer)
4 - Beyond Air, Inc. (0001641631) (Issuer)
4 - Beyond Air, Inc. (0001641631) (Issuer)